A report on the incidence of intestinal 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature.

What It Covers

This review looks at Methylene blue (non-peptide stack partner).

To describe the incidence of intestinal accumulation of (99m)Tc-MDP on bone scans in adult patients, define the patterns of this unusual finding and review the literature on its causes.

A whole-body bone scan and various spot views of the abdomino-pelvic region were obtained with a dual-headed gamma camera to evaluate the intestinal uptake.

Why It Was Studied

In addition to well-known specific conditions for soft-tissue uptake of bone-seeking radiotracers, there is a limited number of reports on intestinal uptake of (99m)Tc-methylene diphosphonate ((99m)Tc-MDP) on bone scans.

Who the Included Studies Covered

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Two thousand, one hundred and forty-four consecutive patients have been evaluated for intestinal (99m)Tc-MDP uptake on bone scans.

Delayed scans were also obtained as well as co-relative imaging and/or colonoscopic studies in some of intestinal uptake patients.

How the Review Was Done

Intestinal uptake was observed visually 3-4 h after the administration of the radiopharmaceutical.

Six patients had delayed scans of the abdomino-pelvic region.

Fourteen patients had comparable scans either a year before or a year later.

What Was Measured

In addition to well-known specific conditions for soft-tissue uptake of bone-seeking radiotracers, there is a limited number of reports on intestinal uptake of (99m)Tc-methylene diphosphonate ((99m)Tc-MDP) on bone scans.

The subject headings attached to it are Body Burden, Bone and Bones, Incidence, Intestinal Mucosa, Intestines, Radiopharmaceuticals and Relative Biological Effectiveness.

What This Means in Plain Language

This is a review of Methylene blue (non-peptide stack partner).

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2006 (Nuclear medicine communications), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.